SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Memecoin on Cronos launched by the Cro Crow community

crow with knife

The crypto memecoin CAW.X, also known as crow with knife, is trending due to its enthusiastic community and recent mentions of potential listings. Community members highlight its unique attributes, multichain functionality across SOL, BSC, CRO, and ETH, and deflationary burn mechanism. Some community members are comparing it to established memecoins and calling it the top memecoin.

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo Inc. is trending due to increased interest in nuclear energy and its potential to power AI data centers, despite the company having no current revenue. The community is debating the stock's high valuation relative to its stage of development, with some anticipating a pullback or secondary offering, while others remain bullish due to the sector's momentum and potential government support. Discussions also highlight comparisons to other energy companies and the potential for a short squeeze.

ARB IOT Group Ltd. is a holding company that engages in the provision of solutions for the integration of IoT systems and devices. It operates through the Internet of Things and Investment Holding and Others segments. The company was founded on March 1, 2022 and is headquartered in Singapore.

ARB IOT Group Ltd

ARBB is trending following news of a large AI server contract, sparking excitement among investors. Community members are actively discussing potential short squeezes due to the stock's low float and high cost to borrow, while others debate the company's long-term potential within the growing IoT sector.

BigBear.ai Holdings, Inc. engages in data-driven decision dominance and advanced analytics that provide its customers with a competitive advantage in a world driven by data that is growing in terms of volume, variety, and velocity. The firm operationalizes artificial intelligence and machine learning at scale through its end-to-end data analytics platform. It deploys its observe, orient and dominate products to customers throughout the defense, intelligence, and commercial markets. The company was founded in 2020 and is headquartered in McLean, VA.

BigBear.ai Holdings Inc

BigBear.ai is trending as traders discuss a potential short squeeze and draw comparisons to other AI defense stocks like Palantir. The community is focused on key resistance levels, anticipating a continued rally and eyeing a move towards higher price targets. Some traders speculate on upcoming news or contract announcements as potential catalysts for further growth.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending due to community discussion surrounding the potential approval of their drug, Deramiocel, for Duchenne Muscular Dystrophy (DMD).  The community is focused on the FDA's feedback from a recent Type A meeting and the potential for accelerated approval, referencing competitor Stealth Bio's recent accelerated approval as a hopeful sign. Discussions also highlight the advocacy efforts of DMD patients and their families, who are actively lobbying for the drug's approval, emphasizing the urgent need for treatment options.

Terner is an AI-powered platform on Solana that enables users to create, deploy, and crowdfund innovative projects through natural language interaction. The platform combines advanced AI capabilities with blockchain technology to democratize project creation, offering tools for building web applications, bots, and various digital solutions while providing automated deployment and investment opportunities for creators and investors alike.

Terner

Terner ($TERNER.X) is trending as the community discusses its potential within the Solana ecosystem, highlighting its AI-powered project creation capabilities. Investors are actively accumulating, citing strong buying pressure and anticipating significant gains. Community members are closely monitoring on-chain stats using Phantom.

B. Riley Financial, Inc. engages in the provision of financial services and solutions to the capital raising and financial advisory needs of public and private firms. It operates through the following segments: Capital Markets, Wealth Management, Financial Consulting, Auction and Liquidation, Communications, and Consumer. The Capital Markets segment provides investment banking, corporate finance, research, wealth management, and sales and trading services to corporate, institutional, and high net worth clients. The Wealth Management segment offers retail brokerage, investment management, and insurance, and tax preparation services. The Financial Consulting segment focuses on a variety of specialized advisory services spanning bankruptcy, restructuring, turnaround management, forensic accounting, crisis and litigation support, appraisal and valuation, real estate, and operations management. The Auction and Liquidation segment deals with retail liquidation services. The Communications segment is composed of a portfolio of companies acquired for attractive risk-adjusted investment return characteristics. The Consumer segment includes Targus and the Brands investment portfolio. The company was founded in 1973 and is headquartered in Los Angeles, CA.

B. Riley Financial Inc

B. Riley Financial is trending as investors await the overdue 10-K filing, with many believing its release will trigger a short squeeze. The community is actively discussing potential catalysts, including interest rate decisions and positive business momentum, while expressing frustration over the delays and concerns about the company's compliance. Despite recent losses and auditor changes, some see a turnaround and significant upside potential once the filings are resolved.

CEA Industries, Inc. engages in in the development, design, and distribution of cultivation technologies for controlled environment agriculture, primarily for cannabis crops. It offers controlled climate systems, controls, and biosecurity cultivation products, and MEP engineering, odor control, and installation support services. The company was founded by Brandy Marie Keen and Stephen Keen on October 15, 2009 and is headquartered in Louisville, CO.

CEA Industries Inc

CEA Industries (BNC) is trending due to discussions around its significant BNB holdings and a recent share buyback announcement, with community members debating the implications of a potentially high short interest and a low float. Some are speculating about a possible short squeeze, while others focus on the company's valuation relative to its assets. The focus remains on the relationship between the stock price, the company's BNB treasury, and potential market manipulation.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media is trending amid discussions around freedom of speech, censorship, and political polarization, particularly following news about Jimmy Kimmel and a resolution honoring Charlie Kirk. The community is fiercely debating the implications of these events, with opinions split along ideological lines. Broader discussions encompass media influence, government overreach, and the role of political figures in shaping public discourse.

"What's Updog?" is a Community Led token.

UpDog

UpDog is trending as community members celebrate its joke-inspired origins and its listing on Jupiter. Many are loading up on the $SOL-based meme coin, while also playfully asking, "What's Updog?" The community is also highlighting the project's donations to animal shelters.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of DexCom (DXCM) declined 10% on Friday after investment firm Hunterbrook Capital disclosed a short position in the stock.Hunterbrook <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://hntrbrk.com/dexcom/">said</a> on Thursday that it has a short position on DXCM based on Hunterbrook Media’s reporting, which stated that after inaccurate readings from Dexcom’s flagship G7 continuous glucose monitor (CGM) device, “some diabetics are ending up in the ICU — or dead.” Hunterbrook Media is an investigative news outlet.The report stated that DexCom made an unauthorized design change to a key component of the G7 that internal studies showed was inferior by “every accuracy metric,” and the company sold the device anyway. This change was revealed during a surprise inspection by the U.S. Food and Drug Administration (FDA), the report stated.Several company executives left the company amid the FDA’s scrutiny and soaring complaints, the report said, while adding that patients are now returning to the G6 or switching to products from competitors, such as Abbott (ABT).Hunterbrook also stated that it has shared its probe with a senior official from the Health and Human Services (HHS) and requested that the FDA intervene. The firm also said that DexCom didn't respond to their requests for comments. The report named people who died or had to be hospitalized following wrong readings by the G7 device, including Billy Sosbe, who died in June, and Diana Bates Knight, who rushed her 6-year-old to the emergency, after the device misread her blood sugar by hundreds of points.“In Dexcom’s crisis, Abbott may see its chance. Our analysis of FDA data shows Dexcom receives more accuracy complaints than its market share predicts; Abbott receives significantly fewer,” Hunterbrook said.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/DXCM">DXCM</a> rose from ‘bearish’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:578/57;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_19_at_2_14_55_PM_png_eb2477f011.webp" alt="DXCM's Sentiment Meter and Message Volume as of 2:15 p.m. ET on Sept. 19, 2025 | Source: Stocktwits" width="578" height="57"><figcaption>DXCM's Sentiment Meter and Message Volume as of 2:15 p.m. ET on Sept. 19, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user opined that DexCom has proven technology and is leading in CGM.<stembedurl>https://stocktwits.com/CmonManGiveMeABreak/message/629329227</stembedurl>Another user, however, opined that the FDA might pull the G7 device from the market.<stembedurl>https://stocktwits.com/buddyopalosam/message/629325830</stembedurl>DXCM stock is down by 13% this year and by 5% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/equity/markets/kalvista-pharmaceuticals-hereditary-angioedema-drug-approved-in-eu-switzerland/chD3BkIR3TW">KalVista Pharmaceuticals’ Hereditary Angioedema Drug Approved In EU, Switzerland: Retail Sees Stock Rallying To $22 In A Year</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the DexCom logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

DexCom Stock Slumps 10% After Hunterbrook Media Investigation Raises Concerns About Its G7 Device

Hunterbrook Capital said on Thursday that it has a short position in DXCM stock based on Hunterbrook Media’s reporting, which stated that some diabetics died after inaccurate readings from Dexcom’s G7  device.

Equity

Hunterbrook Capital said on Thursday that it has a short position in DXCM stock based on Hunterbrook Media’s reporting, which stated that after inaccurate readings from Dexcom’s G7 continuous glucose monitor device, some diabetics are ending up in the ICU or dead.


Investing in the Age of Longevity: Silver Economy Stocks in Focus

AbbVie, Amgen, Stryker and Dexcom are tapping into the booming silver economy with new therapies, tech and acquisitions aimed at aging populations.

Why Is DexCom (DXCM) Down 7% Since Last Earnings Report?

DexCom (DXCM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Dexcom Announces Upcoming Conference Presentations

DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on the company at the following upcoming investor conferences: The 2025 Wells Fargo Healthcare Conference on...

DexCom Expands Access and Innovation While Balancing Headwinds

DXCM grows on type 2 access, Stelo adoption, and new sensor launches, but faces margin pressures, competition and leadership transition.

Trinity Biotech's Redesigned CGM Sensor Favored by New Clinical Data

TRIB's needle-free CGM+ sensor shows accurate 15-day results with no calibration, slashing costs and boosting access.

Abbott's Q2 Diabetes Care Sales Rise 19.6%: What's Backing It?

ABT's Diabetes Care sales surge 19.6% in Q2, fueled by strong U.S. demand and new OTC approvals for its CGM systems.

DexCom Stock Falls Despite Q2 Earnings Beat & 2025 Sales View Raise

DXCM beats on Q2 earnings and raises 2025 sales guidance, but shares dip as margin pressure dampens investor enthusiasm.

Compared to Estimates, DexCom (DXCM) Q2 Earnings: A Look at Key Metrics

Although the revenue and EPS for DexCom (DXCM) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

DexCom (DXCM) Q2 Earnings and Revenues Top Estimates

DexCom (DXCM) delivered earnings and revenue surprises of +6.67% and +3.06%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6, Dexcom G7, Dexcom Stelo, Dexcom Share, Dexcom Real-Time API, and Dexcom ONE. The company was founded by John F. Burd on May 13, 1999 and is headquartered in San Diego, CA.

Dexcom Inc

Just the one

Three

Four

The Fed just cut rates. How many cuts do you expect in all of 2025? 
 
*Powered by Polymarket

Current Price	$67.45
Prev Close	$75.78
Open	$75.00
Dividend Yield	0.00%
50-Day Moving Average	$80.42
Beta	0.91
Avg. Volume	4.13M
PE Ratio	53.05

52-Week High	$93.25
52-Week Low	$57.52
Market Capitalization	$29.72B
EPS (Annual)	$1.42
Price to Book	11.55
Revenue Per Employee	$391,553.40
Enterprise Value/EBITDA	N/A

DXCM
Dexcom Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest DXCM News

DXCM Dexcom Inc